Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab Tolvorlimab as Neoadjuvant Immunotherapy for Locally Advanced Gastric Adenocarcinoma With MSI-H/dMMR
NCT07595523Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jun 2026
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab + tuvonralimab in gastric adenocarcinoma, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Pathological Complete Response Rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT07595523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07595523.